glp-1 drugs and cancer may be linked to a lower risk of progression, according to new research that will be presented next week at the American Society of Clinical Oncology's annual meeting Weight-loss drugs now linked to

95% CI, 0.37-0.73

& Kluger, M

317K, 85K, 84K, 79K or 61K particles of taspoglutide complex) was 3D auto-refined, and the best resolved classes of taspoglutide complex (158K particles) was further refined and post processed with a G protein mask to generate a final map of the AHD

Studies on insulinotrophic and anorexigenic effects of GLP-1 only recently have led to the development of a new class of drugs, often referred to as incretin drugs, which act as GLP-1 receptor agonists (GLP-1RAs) and are currently implemented in therapy for T2DM [13]

Some recent clinical trials have also examined combination therapies with other antidiabetic agents, including dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose cotransporter-2 (SGLT2) inhibitors, or metformin for potential additive outcomes [25]